Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher P Fox

Showing results (101-110 of 127) with videos related to

Pageof 13
Sort By:
British Journal of Haematology|August 9, 2022
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative GroupSara Steffanoni, Teresa Calimeri, Alice Laurenge, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
The New England Journal of Medicine|December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, David A Cairns, Adrian Bloor, et al.
Pageof 13

Showing results (101-110 of 127) with videos related to

Sort By:
Pageof 13
British Journal of Haematology|August 9, 2022
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative GroupSara Steffanoni, Teresa Calimeri, Alice Laurenge, et al.
Blood Advances|June 10, 2026
Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLOJeremy S Abramson, William Townsend, Christopher P Fox, et al.
The Lancet. Haematology|May 25, 2024
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T-cell lymphoma (ORACLE): an open-label randomised, phase 3 studyJehan Dupuis, Emmanuel Bachy, Franck Morschhauser, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|October 1, 2025
Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Bone Marrow Transplantation|October 1, 2025
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G CommitteeGandhi Damaj, Adèle de Masson, Peter Dreger, et al.
Haematologica|October 27, 2022
International multicenter retrospective analysis of thiotepa-based autologous stem cell transplantation for secondary central nervous system lymphomaJahanzaib Khwaja, Amy A Kirkwood, Lisa K Isbell, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
The Lancet. Oncology|May 4, 2023
Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trialPeter Hillmen, Alexandra Pitchford, Adrian Bloor, et al.
Bone Marrow Transplantation|May 6, 2018
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working PartiesPeter Dreger, Mauricette Michallet, Paul Bosman, et al.
The New England Journal of Medicine|December 11, 2023
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual DiseaseTalha Munir, David A Cairns, Adrian Bloor, et al.
Pageof 13